J Exp Clin Cancer Res:SPOP能够通过促进ATF2泛素化和降解来抑制前列腺癌恶化

2018-07-28 AlexYang MedSci原创

前列腺癌外显子组和基因组的二代测序技术已经鉴定了大量的遗传变异。SPOP(斑点型POZ蛋白)在原发性前列腺癌中是最常见的基因变异之一,表明了SPOP也许是前列腺癌驱使因子之一。最近,有研究人员调查了SPOP变异怎样促进前列腺癌的发展和恶化。研究人员通过酵母双杂交筛选鉴定SPOP肿瘤抑制功能的分子调控因子,利用免疫沉淀和蛋白印迹来分析SPOP与ATF2之间的互作。研究人员还利用Transwell试验

前列腺癌外显子组和基因组的二代测序技术已经鉴定了大量的遗传变异。SPOP(斑点型POZ蛋白)在原发性前列腺癌中是最常见的基因变异之一,表明了SPOP也许是前列腺癌驱使因子之一。最近,有研究人员调查了SPOP变异怎样促进前列腺癌的发展和恶化。

研究人员通过酵母双杂交筛选鉴定SPOP肿瘤抑制功能的分子调控因子,利用免疫沉淀和蛋白印迹来分析SPOP与ATF2之间的互作。研究人员还利用Transwell试验分析细胞迁移和侵入,并通过免疫组化分析患者肿瘤样本中的蛋白水平。研究发现,ATF2是 SPOP-CUL3-RBX1 E3泛素连接酶复合物的真底物。SPOP能够识别ATF2多重Ser/Thr (S/T)富集的降解决定位点,并且通过泛素蛋白酶体降解途径激发ATF2的降解。明显的是,在前列腺癌细胞中,前列腺癌相关的SPOP变异在促进ATF2降解上存在缺陷,这也导致了促进前列腺癌细胞增殖、迁移和侵入的发生。

最后,研究人员指出,SPOP能够促进ATF2的泛素化和降解,并且ATF2是SPOP去激活诱导的细胞增殖、迁移和侵入的重要调控因子。

原始出处:

Ma J, Chang K, Peng J et al. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression. J Exp Clin Cancer Res. 11 July 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1993131, encodeId=f418199313183, content=<a href='/topic/show?id=dd881663866' target=_blank style='color:#2F92EE;'>#SPOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16638, encryptionId=dd881663866, topicName=SPOP)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sat Aug 18 11:45:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336326, encodeId=86d633632694, content=前列腺癌的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 10:58:57 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335326, encodeId=26ae335326ae, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Jul 31 13:02:41 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334945, encodeId=d49c3349450d, content=好好学习天天学习认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun Jul 29 16:43:10 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334709, encodeId=e19e334e0965, content=希望早日用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 28 11:15:32 CST 2018, time=2018-07-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1993131, encodeId=f418199313183, content=<a href='/topic/show?id=dd881663866' target=_blank style='color:#2F92EE;'>#SPOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16638, encryptionId=dd881663866, topicName=SPOP)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sat Aug 18 11:45:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336326, encodeId=86d633632694, content=前列腺癌的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 10:58:57 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335326, encodeId=26ae335326ae, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Jul 31 13:02:41 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334945, encodeId=d49c3349450d, content=好好学习天天学习认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun Jul 29 16:43:10 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334709, encodeId=e19e334e0965, content=希望早日用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 28 11:15:32 CST 2018, time=2018-07-28, status=1, ipAttribution=)]
    2018-08-04 liumin1987

    前列腺癌的治疗。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1993131, encodeId=f418199313183, content=<a href='/topic/show?id=dd881663866' target=_blank style='color:#2F92EE;'>#SPOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16638, encryptionId=dd881663866, topicName=SPOP)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sat Aug 18 11:45:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336326, encodeId=86d633632694, content=前列腺癌的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 10:58:57 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335326, encodeId=26ae335326ae, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Jul 31 13:02:41 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334945, encodeId=d49c3349450d, content=好好学习天天学习认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun Jul 29 16:43:10 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334709, encodeId=e19e334e0965, content=希望早日用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 28 11:15:32 CST 2018, time=2018-07-28, status=1, ipAttribution=)]
    2018-07-31 一个字-牛

    学习了谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1993131, encodeId=f418199313183, content=<a href='/topic/show?id=dd881663866' target=_blank style='color:#2F92EE;'>#SPOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16638, encryptionId=dd881663866, topicName=SPOP)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sat Aug 18 11:45:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336326, encodeId=86d633632694, content=前列腺癌的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 10:58:57 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335326, encodeId=26ae335326ae, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Jul 31 13:02:41 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334945, encodeId=d49c3349450d, content=好好学习天天学习认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun Jul 29 16:43:10 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334709, encodeId=e19e334e0965, content=希望早日用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 28 11:15:32 CST 2018, time=2018-07-28, status=1, ipAttribution=)]
    2018-07-29 zwjnj2

    好好学习天天学习认真学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1993131, encodeId=f418199313183, content=<a href='/topic/show?id=dd881663866' target=_blank style='color:#2F92EE;'>#SPOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16638, encryptionId=dd881663866, topicName=SPOP)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sat Aug 18 11:45:00 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336326, encodeId=86d633632694, content=前列腺癌的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 10:58:57 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335326, encodeId=26ae335326ae, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Jul 31 13:02:41 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334945, encodeId=d49c3349450d, content=好好学习天天学习认真学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun Jul 29 16:43:10 CST 2018, time=2018-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334709, encodeId=e19e334e0965, content=希望早日用于临床, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 28 11:15:32 CST 2018, time=2018-07-28, status=1, ipAttribution=)]
    2018-07-28 医者仁心5538

    希望早日用于临床

    0

相关资讯

Sci Rep:利用Gd标签的红细胞产生的多参数MRI图谱来阐释前列腺癌的表型和阶段

前列腺癌(PCa)在西方国家中是第二大最常见的癌症,也是男性癌症相关致死的第5大死因。早期、更加精确的和非侵入性的创新性诊断工具的开发在医学上时迫切需要的。血管容积(Vv)和组织缺氧是2中最常见的重要肿瘤标志。因此,最近,有研究人员利用MRI技术在TRAMP小鼠中对上述2中标志进行了评估,并利用体外标记Gd-HPDO3A 或者Gd-DOTP的自体同源红细胞(RBCs)复合物分别进行注射来对上述2中

盘点:前列腺癌治疗研究盘点

前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌(腺泡腺癌)、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上,因此,通常我们所说的前列腺癌就是指前列腺腺癌。梅斯医学小编整理了近期前列腺癌的研究进展,与大家一起分享学习!【1】Cancer Causes Control:进行局部前列腺癌雄激素阻

Sci Rep:不同放射治疗在局部前列腺癌患者中的比较

最近,有研究人员为了比较低剂量短距离放射治疗(LDR-BT)和图像指导强度的放射治疗(IG-IMRT)在局部前列腺癌中的治疗效果,他们调查了488名LDR-BT患者和269名IG-IMRT患者。研究发现,IG-IMRT用于治疗更加年老的和晚期的疾病,并且激素治疗要比LDR-BT多,其中不包括T3b-T4肿瘤和起始PSA>50ng/ml的患者。IG-IMRT和LDR-BT中实际的5年无生化失败

Radiology:镓68 PSMA-11 PET/MR成像在中高危前列腺癌中的价值

本研究旨在报告双时相镓68(68Ga)PSMA 11PET/MRI在中高危前列腺癌切除术前的诊断价值,将结果发表在radiology上。

Cancer Sci:人类去势难治性前列腺中卡巴他赛抗性机制分析

卡巴他赛(CBZ)是批准通过的用于抗多烯紫杉醇去势难治性前列腺癌(CRPC)的药物。然而,CBZ治疗CRPC的效果是有限的,并且没有有效的治疗措施来治疗CBZ抗性CRPC。最近,有研究人员指出,为了调查CBZ抗性机制,建立一种CBZ抗性细胞系是急切需要的。利用2年的时间,他们通过逐渐增加CBZ浓度来培育DU145和PC3细胞,从而产生CBZ抗性CRPC细胞系。研究人员还利用基因芯片和流失细胞仪分析

BMC Cancer:前列腺癌临床癌症护理质量指标研究

癌症护理质量(QoCC)是世界范围内护理提供者、管理者和购买者需要考虑的重要内容。最近,有研究人员基于群体水平,呈现了一些基于证据的前列腺癌(PC)护理质量指标(QI),并且与现存可利用文献中的数据资料进行了比较。研究包括了所有瑞典提契诺州的3年(01.01.2011-31.12.2013)分析期间诊断为PC的患者。研究发现,在为期3年的分析中,总共检测到了700名PC患者:其中的78.3%是通过